Drug Profile
MT 2765
Alternative Names: MT-2765Latest Information Update: 04 Aug 2023
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Mitsubishi Tanabe Pharma Corporation; Shanghai Pharmaceuticals Holding
- Class Antihypertensives; Cardiovascular therapies
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Hypertension
- No development reported Cardiovascular disorders
Most Recent Events
- 25 Jul 2023 No development reported - Phase-III for Cardiovascular disorders in China (unspecified route) (Mitsubishi Tanabe Pharma Corporation pipeline, August 2023)
- 30 Jun 2023 Preregistration for Hypertension in China (unspecified route) (Mitsubishi Tanabe Pharma Corporation pipeline, August 2023)
- 04 Oct 2022 Phase-III clinical trials in Hypertension in China (unspecified route)